Ammonium Lactate
CAS 515-98-0
Ammonium Lactate (CAS 515-98-0) is a Phase 4 pharmaceutical compound with 0 bioactivity targets and 364 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Dermatitis atopic | 14 | 38.096 | 10012438 |
| Product dose omission issue | 39 | 29.544 | 10084406 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| AMMONIUM LACTATE | 215247 | SU | MTHSPL |
| ammonium lactate | 215247 | PIN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Ammonium Lactate used for in pharmaceutical contexts?
Ammonium Lactate (CAS 515-98-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Ammonium Lactate?
Ammonium Lactate has 364 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Dermatitis atopic, Product dose omission issue, Abdominal discomfort, Abdominal pain, Abdominal pain upper. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Ammonium Lactate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Ammonium Lactate with EU status "permitted".
What clinical phase is Ammonium Lactate in?
Ammonium Lactate is rendered with ChEMBL max phase 4 (approved).